CAI
Caris Life SciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Composite grade A from latest DB weights. Momentum 98.1 / Value 55.8
Posture
Constructive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
98
Value
56
Sentiment
N/A
Setup hits (3d)
6 · Net Bullish
AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $32.08
Why
Momentum98 · Δ7d -0.3
Value56 · Δ7d -0.2
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Mixed signals. Wait for cleaner trend confirmation.
Catalyst clock
No dated catalyst is available.
Lead driver: Value · See fundamentals
Momentum
98
15% active weight
Current posture
7d trendImproving
Δ7d
-0.3
Δ21d
-1.0
Value
56
85% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-1.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.1 / Value 55.8
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$9.04B
Beta
-
Shares Out
282.6M
P/E (TTM) · Derived
-16.8
P/S (TTM)
-
P/FCF (TTM) · Derived
77.73
Rev YoY
+45.4%
EPS YoY
-99.9%
Gross Margin
+69.7%
Op Margin
+15.5%
Net Debt
-$372.41M
Current Ratio
5.53
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data